PATENT CLAIM ANALYSIS

Application Number: 15774632
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["424", "001650"]

Abstract:
The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound comprising the same, and a pharmaceutical composition for treating or diagnosing prostate cancer comprising the same as an active ingredient. The peptide thiourea derivative of the present invention is excellent in stability in human serum when it is administered in vivo and not only binds well to PSMA expressed in prostate cancer but also inhibits excellently PSMA at a low concentration. Besides, the derivative of the invention has a high water-solubility and can be excreted through the kidney not through the bile passage so that a clear image of the tumor region of prostate cancer can be obtained. Therefore, the derivative of the present invention can be effectively used as a pharmaceutical composition for treating and diagnosing prostate cancer.

Claim (Index 6):
A pharmaceutical composition for treating or diagnosing prostate cancer comprising the labeled compound of  claim 4  as an active ingredient.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 93.0
- Lexical Diversity: 1.8481
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14553157', '15203602', '13566849', '15385490', '14126296']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7274499386421989
- 35 USC 102 Novelty (BERT): 0.5169909867535251
- Combined Prediction Score: 0.7064040434533315
- Mean Citation Score: 284.68246800000014
- Max Citation Score: 289.91586
- Similarity Product: 178.15643698135972

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test